ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: A reciprocal translocation between chromosomes 9 and 22 (t(9;22)–(q34;q11)), resulting in fusion protein BCR–ABL1 is a major contributing event to CML and has been a dominant therapeutic target (30, 31) (Table 3).